China Medical System Secures Exclusive Rights to Baiyiyuan Biotech’s Implant in Greater China
China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with Shanghai-based...
HKG: 0867
China Medical System Holdings’ Desidustat NDA Accepted for Review by China’s NMPA
China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...
China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...
China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases
China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement...
China Medical System Gets Green Light for Phase III Clinical Trial of Opzelura in Atopic Dermatitis
China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...
CMS Secures NMPA Approval for Clinical Trials of TYK2 Inhibitor CMS-D001 and GnRH Antagonist CMS-D002
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received clinical...
China Medical System Reclaims Rights to Velphoro from WinHealth in Greater China
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a rights assignment agreement with...
China Medical System Holdings Secures Exclusive Rights to Promote Xihong Biopharma’s Aesthetic Fillers
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a licensing agreement with Jiangxi...
China Medical System Expands into Southeast Asia with Singapore Manufacturing Plant Lease
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that its joint venture, PharmaGend...
China Medical System Gets NMPA Green Light for Phase III Vitiligo Study with Ruxolitinib Cream
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from...
China Medical System’s Methotrexate Injection Receives NMPA Review for Rheumatoid Arthritis Indication
China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...
Neurodawn Pharmaceutical and China Medical System Holdings Ink Licensing Deal for Y-3
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has entered into a significant licensing deal with China Medical...
China Medical System’s Diazepam Nasal Spray Receives NMPA Approval for Cluster Seizures
China-based China Medical System Holdings Ltd (CMS; HKG: 0867) has announced receiving New Drug Application...
CMS Receives NMPA Approval for Tildrakizumab for Plaque Psoriasis Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced receiving marketing approval from the National...
CMS Receives NMPA Approval for Clinical Study of Tetravalent BsAb for nAMD
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from...
Cosmo Pharmaceuticals’ Lumeblue Completes Phase III Trial in China
Ireland-based Cosmo Pharmaceuticals N.V. (OTCMKTS: CMOPF) revealed that its Lumeblue (methylthioninium chloride) diagnostic agent has...
Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange
China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...
China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia
China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...
Trinomab Biotech Raises RMB 750 Million in Pre-IPO Financing Round
China-based Trinomab Biotech Co., Ltd reportedly raised RMB 750 million (USD 104.5 million) in a...
China Medical System Licenses Botulinum Toxin from South Korea’s BMI Korea
China Medical System Holdings (CMS; HKG: 0867) has announced the establishment of a licensing agreement...